Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Claudio Jommi

Showing results (61-70 of 84) with videos related to

Pageof 9
Sort By:
International Journal of Technology Assessment in Health Care|May 24, 2022
Facilitating More Efficient Negotiations for Innovative Therapies: A Value-Based Negotiation Framework - CorrigendumAmanda Whittal, Claudio Jommi, Gérard De Pouvourville, et al.
International Journal of Technology Assessment in Health Care|March 11, 2022
Facilitating [corrected] More Efficient Negotiations for Innovative Therapies: A Value-Based Negotiation FrameworkAmanda Whittal, Claudio Jommi, Gérard De Pouvourville, et al.
BMC Health Services Research|January 23, 2024
Cost of implementing CAR-T activity and managing CAR-T patients: an exploratory studyMaria Caterina Cavallo, Marianna Cavazza, Francesca Bonifazi, et al.
Bioactive Materials|July 17, 2023
Mesenchymal stem cell secretome and extracellular vesicles for neurodegenerative diseases: Risk-benefit profile and next steps for the market accessLorella Giovannelli, Elia Bari, Claudio Jommi, et al.
Health Policy (Amsterdam, Netherlands)|May 18, 2019
Determinants of price negotiations for new drugs. The experience of the Italian Medicines AgencyFederico Villa, Michaela Tutone, Gianluca Altamura, et al.
Applied Health Economics and Health Policy|August 9, 2018
Projecting Pharmaceutical Expenditure in EU5 to 2021: Adjusting for the Impact of Discounts and RebatesJaime Espin, Michael Schlander, Brian Godman, et al.
Health Economics Review|November 26, 2025
Horizon scanning and drug expenditure for rare diseases: three-year predictive model in Italy 2025-2027Andrea Marcellusi, Daniela Cazzato, Giulio Guarnotta, et al.
Frontiers in Medicine|June 16, 2023
Comparative analysis of CAR T-cell therapy access for DLBCL patients: associated challenges and solutions in the four largest EU countriesMiguel Á Canales Albendea, Pier Luigi Canonico, Guillaume Cartron, et al.
Pharmacoeconomics - Open|April 7, 2018
The Cost of Patients with Chronic Kidney Failure Before Dialysis: Results from the IRIDE Observational StudyClaudio Jommi, Patrizio Armeni, Margherita Battista, et al.
Journal of Market Access & Health Policy|July 26, 2017
Unlocking the potential of established products: toward new incentives rewarding innovation in EuropeGabrielle Nayroles, Sandrine Frybourg, Sylvie Gabriel, et al.
Pageof 9

Showing results (61-70 of 84) with videos related to

Sort By:
Pageof 9
International Journal of Technology Assessment in Health Care|May 24, 2022
Facilitating More Efficient Negotiations for Innovative Therapies: A Value-Based Negotiation Framework - CorrigendumAmanda Whittal, Claudio Jommi, Gérard De Pouvourville, et al.
International Journal of Technology Assessment in Health Care|March 11, 2022
Facilitating [corrected] More Efficient Negotiations for Innovative Therapies: A Value-Based Negotiation FrameworkAmanda Whittal, Claudio Jommi, Gérard De Pouvourville, et al.
BMC Health Services Research|January 23, 2024
Cost of implementing CAR-T activity and managing CAR-T patients: an exploratory studyMaria Caterina Cavallo, Marianna Cavazza, Francesca Bonifazi, et al.
Bioactive Materials|July 17, 2023
Mesenchymal stem cell secretome and extracellular vesicles for neurodegenerative diseases: Risk-benefit profile and next steps for the market accessLorella Giovannelli, Elia Bari, Claudio Jommi, et al.
Health Policy (Amsterdam, Netherlands)|May 18, 2019
Determinants of price negotiations for new drugs. The experience of the Italian Medicines AgencyFederico Villa, Michaela Tutone, Gianluca Altamura, et al.
Applied Health Economics and Health Policy|August 9, 2018
Projecting Pharmaceutical Expenditure in EU5 to 2021: Adjusting for the Impact of Discounts and RebatesJaime Espin, Michael Schlander, Brian Godman, et al.
Health Economics Review|November 26, 2025
Horizon scanning and drug expenditure for rare diseases: three-year predictive model in Italy 2025-2027Andrea Marcellusi, Daniela Cazzato, Giulio Guarnotta, et al.
Frontiers in Medicine|June 16, 2023
Comparative analysis of CAR T-cell therapy access for DLBCL patients: associated challenges and solutions in the four largest EU countriesMiguel Á Canales Albendea, Pier Luigi Canonico, Guillaume Cartron, et al.
Pharmacoeconomics - Open|April 7, 2018
The Cost of Patients with Chronic Kidney Failure Before Dialysis: Results from the IRIDE Observational StudyClaudio Jommi, Patrizio Armeni, Margherita Battista, et al.
Journal of Market Access & Health Policy|July 26, 2017
Unlocking the potential of established products: toward new incentives rewarding innovation in EuropeGabrielle Nayroles, Sandrine Frybourg, Sylvie Gabriel, et al.
Pageof 9